Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acumen Pharmaceuticals, Inc.

1.06
+0.159217.67%
Post-market: 1.090.0291+2.75%18:13 EDT
Volume:386.10K
Turnover:369.60K
Market Cap:64.21M
PE:-0.62
High:1.07
Open:0.8700
Low:0.8551
Close:0.9008
Loading ...

Company Profile

Company Name:
Acumen Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
61
Office Location:
1210-1220 Washington St.,Suite 210,Newton,Massachusetts,United States
Zip Code:
02465
Fax:
- -
Introduction:
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Directors

Name
Position
Daniel O'Connell
President and Chief Executive Officer and Director
Jeffrey L. Ives
Director
Jeffrey Sevigny
Director
Laura Stoppel
Director
Nathan B. Fountain
Director
Sean Stalfort
Director

Shareholders

Name
Position
Daniel O'Connell
President and Chief Executive Officer and Director
Russell Barton
Chief Operating Officer
Matthew Zuga
Chief Financial Officer and Chief Business Officer
Eric Siemers
Chief Medical Officer